Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SO YEON PAEK

Allopathic & Osteopathic Physicians Dermatology

NPI
1790079184
CMS profile
307759
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$94,442.96

258 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 6; records 251–258 of 258 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SO YEON PAEK

NPI 1790079184 · CMS profile ID 307759

Allopathic & Osteopathic Physicians / Dermatology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–258 of 258 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790079184?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SO YEON PAEK, NPI 1790079184, CMS profile ID 307759. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–258 of 258 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790079184?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SO YEON PAEK, NPI 1790079184, CMS profile ID 307759. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–258 of 258 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790079184?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SO YEON PAEK, NPI 1790079184, CMS profile ID 307759, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–258 of 258 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1790079184?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

258 matching records · $94,442.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 258 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–258 of 258.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $12.3901/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658160011 CMS
Mayne Pharma Inc. $10.2401/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705513213 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.5601/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684597205 CMS
AbbVie, Inc. $18.9201/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647831849 CMS
AbbVie, Inc. $89.2101/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647831959 CMS
AbbVie, Inc. $26.7101/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647831961 CMS
AbbVie, Inc. $34.0001/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647831963 CMS
AbbVie, Inc. $5,175.0001/04/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647831965 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $94,442.96 258
PY2020 $46,924.75 126
PY2021 $34,359.02 64
PY2022 $141,123.81 190
PY2023 $130,934.00 195
PY2024 $164,023.20 258
PY2025 $200,352.11 298

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $929,852.38 525
PY2024 Recipient $973.10 15
PY2024 Principal investigator $988,719.22 727
PY2023 Principal investigator $312,764.14 163
PY2021 Principal investigator $37,644.30 6
PY2020 Recipient $4,375.00 1
PY2020 Principal investigator $159,230.62 18
PY2019 Principal investigator $222,782.60 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

525 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $350.00 12/31/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202535179
Principal investigator 1 ABBVIE INC. $1,100.00 12/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202532002
Principal investigator 1 ABBVIE INC. $105.54 12/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202531712
Principal investigator 1 ABBVIE INC. $81.00 12/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202531714
Principal investigator 1 ABBVIE INC. $31.05 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202531560
Principal investigator 1 ABBVIE INC. $31.05 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202531562
Principal investigator 1 Incyte Corporation $350.00 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599543
Principal investigator 1 Incyte Corporation $2,246.00 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599689
Principal investigator 1 ABBVIE INC. $22.00 12/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202530570
Principal investigator 1 ABBVIE INC. $29.70 12/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202530574
Principal investigator 1 Incyte Corporation $125.00 12/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599502
Principal investigator 1 Incyte Corporation $125.00 12/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599506
Principal investigator 1 Incyte Corporation $125.00 12/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599509
Principal investigator 1 Incyte Corporation $125.00 12/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599512
Principal investigator 1 Incyte Corporation $125.00 12/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599519
Principal investigator 1 Incyte Corporation $350.00 12/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599523
Principal investigator 1 ABBVIE INC. $44.55 12/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202529988
Principal investigator 1 ABBVIE INC. $165.00 12/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202529996
Principal investigator 1 ABBVIE INC. $29.70 12/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202530046
Principal investigator 1 ABBVIE INC. $29.70 12/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202530048
Principal investigator 1 ABBVIE INC. $350.00 12/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202530050
Principal investigator 1 Incyte Corporation $125.00 12/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599526
Principal investigator 1 Incyte Corporation $125.00 12/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599531
Principal investigator 1 Incyte Corporation $125.00 12/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599535
Principal investigator 1 Incyte Corporation $125.00 12/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599539
Principal investigator 1 ABBVIE INC. $105.54 12/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202529618
Principal investigator 1 Incyte Corporation $350.00 12/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599554
Principal investigator 1 Incyte Corporation $100.00 12/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599650
Principal investigator 1 ABBVIE INC. $3,438.45 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202526754
Principal investigator 1 ABBVIE INC. $29.70 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202526756
Principal investigator 1 ABBVIE INC. $1,862.00 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202526836
Principal investigator 1 ABBVIE INC. $51,444.17 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202526838
Principal investigator 1 ABBVIE INC. $44.55 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527030
Principal investigator 1 ABBVIE INC. $2,100.00 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527236
Principal investigator 1 ABBVIE INC. $1,510.00 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527310
Principal investigator 1 ABBVIE INC. $81.00 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527312
Principal investigator 1 Incyte Corporation $350.00 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240599470
Principal investigator 1 Incyte Corporation $83.00 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599696
Principal investigator 1 ABBVIE INC. $22.00 12/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202526362
Principal investigator 1 Incyte Corporation $750.00 12/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240599436
Principal investigator 1 Incyte Corporation $350.00 12/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240599458
Principal investigator 1 ABBVIE INC. $3,510.00 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202526168
Principal investigator 1 Incyte Corporation $59.13 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599433
Principal investigator 1 Incyte Corporation $49.36 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599439
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599451
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599454
Principal investigator 1 Incyte Corporation $91.60 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599462
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599487
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599491
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599495
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599498
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599565
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599573
Principal investigator 1 Incyte Corporation $16.18 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599582
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599586
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599590
Principal investigator 1 Incyte Corporation $7.42 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599594
Principal investigator 1 Incyte Corporation $16.44 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599598
Principal investigator 1 Incyte Corporation $16.44 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599602
Principal investigator 1 Incyte Corporation $16.44 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599606
Principal investigator 1 Incyte Corporation $16.44 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599610
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599623
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599626
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599630
Principal investigator 1 Incyte Corporation $21.33 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599640
Principal investigator 1 Incyte Corporation $54.76 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599655
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599657
Principal investigator 1 ABBVIE INC. $81.00 11/26/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202525502
Principal investigator 1 ABBVIE INC. $165.00 11/26/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202525670
Principal investigator 1 Incyte Corporation $3,041.00 11/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599446
Principal investigator 1 Incyte Corporation $2,111.00 11/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599619
Principal investigator 1 ABBVIE INC. $22.00 11/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202524816
Principal investigator 1 ABBVIE INC. $105.54 11/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202524818
Principal investigator 1 ABBVIE INC. $29.70 11/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202524638
Principal investigator 1 Incyte Corporation $83.00 11/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599466
Principal investigator 1 Incyte Corporation $2,881.00 11/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599483
Principal investigator 1 Incyte Corporation $4,308.00 11/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599584
Principal investigator 1 Incyte Corporation $236.00 11/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599614
Principal investigator 1 Incyte Corporation $4,284.00 11/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599685
Principal investigator 1 ABBVIE INC. $436.80 11/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523895
Principal investigator 1 Incyte Corporation $100.00 11/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599647
Principal investigator 1 ABBVIE INC. $105.54 11/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523295
Principal investigator 1 ABBVIE INC. $81.00 11/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523297
Principal investigator 1 ABBVIE INC. $81.00 11/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202523299
Principal investigator 1 ABBVIE INC. $39,951.94 11/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522009
Principal investigator 1 ABBVIE INC. $5,761.35 11/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522839
Principal investigator 1 ABBVIE INC. $29,665.95 11/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520421
Principal investigator 1 Incyte Corporation $100.00 11/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599546
Principal investigator 1 Incyte Corporation $100.00 11/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599550
Principal investigator 1 ABBVIE INC. $29.70 10/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202518759
Principal investigator 1 ABBVIE INC. $29.70 10/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202518779
Principal investigator 1 ABBVIE INC. $81.00 10/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202518781
Principal investigator 1 ABBVIE INC. $29.70 10/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202518289
Principal investigator 1 ABBVIE INC. $29.70 10/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202518095
Principal investigator 1 ABBVIE INC. $31.05 10/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202517565
Principal investigator 1 ABBVIE INC. $101.25 10/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202517567
Principal investigator 1 ABBVIE INC. $101.25 10/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202517593
Principal investigator 1 Incyte Corporation $3,041.00 10/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599558
Principal investigator 1 Incyte Corporation $563.00 10/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599562
Principal investigator 1 ABBVIE INC. $29.70 10/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202517203
Principal investigator 1 ABBVIE INC. $105.54 10/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202517223
Principal investigator 1 Incyte Corporation $750.00 10/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599634
Principal investigator 1 ABBVIE INC. $165.00 10/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202516531
Principal investigator 1 ABBVIE INC. $27,416.69 10/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514815
Principal investigator 1 ABBVIE INC. $9,505.65 10/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515005
Principal investigator 1 ABBVIE INC. $29.70 10/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202513521
Principal investigator 1 Incyte Corporation $2,517.00 10/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599578
Principal investigator 1 ABBVIE INC. $81.00 10/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202513439
Principal investigator 1 Incyte Corporation $2,000.00 10/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599442
Principal investigator 1 Incyte Corporation $1,985.00 10/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599476
Principal investigator 1 Incyte Corporation $1,985.00 10/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599479
Principal investigator 1 Incyte Corporation $15,750.00 10/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599569
Principal investigator 1 Incyte Corporation $2,500.00 10/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599637
Principal investigator 1 Incyte Corporation $1,500.00 10/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240599643
Principal investigator 1 ABBVIE INC. $31.05 09/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202512314
Principal investigator 1 ABBVIE INC. $5,000.00 09/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202512068
Principal investigator 1 ABBVIE INC. $355.00 09/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511882
Principal investigator 1 ABBVIE INC. $29.70 09/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202511890
Principal investigator 1 Incyte Corporation $4,284.00 09/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599682
Principal investigator 1 ABBVIE INC. $105.54 09/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511418
Principal investigator 1 ABBVIE INC. $44.55 09/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202511496
Principal investigator 1 ABBVIE INC. $29.70 09/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202511498
Principal investigator 1 ABBVIE INC. $5,000.00 09/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511180
Principal investigator 1 ABBVIE INC. $29.70 09/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511014
Principal investigator 1 ABBVIE INC. $165.00 09/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202510848
Principal investigator 1 Incyte Corporation $44.00 09/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599317
Principal investigator 1 Incyte Corporation $750.00 09/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599325
Principal investigator 1 ABBVIE INC. $29.70 09/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202510656
Principal investigator 1 Incyte Corporation $1,783.00 09/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599291
Principal investigator 1 Incyte Corporation $70.00 09/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599288
Principal investigator 1 Incyte Corporation $100.00 09/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599302
Principal investigator 1 ABBVIE INC. $6,000.00 09/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202509260
Principal investigator 1 ABBVIE INC. $5,761.35 09/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509262
Principal investigator 1 ABBVIE INC. $38,938.49 09/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509264
Principal investigator 1 ABBVIE INC. $105.54 09/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509390
Principal investigator 1 Incyte Corporation $100.00 09/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599320
Principal investigator 1 Incyte Corporation $249.08 09/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599340
Principal investigator 1 ABBVIE INC. $2,500.00 08/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202505965
Principal investigator 1 ABBVIE INC. $3,510.00 08/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505973
Principal investigator 1 ABBVIE INC. $29.70 08/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505589
Principal investigator 1 Incyte Corporation $2,038.00 08/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599678
Principal investigator 1 Incyte Corporation $350.00 08/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599263
Principal investigator 1 Incyte Corporation $3,041.00 08/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599273
Principal investigator 1 Incyte Corporation $100.00 08/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599284
Principal investigator 1 Incyte Corporation $2,104.00 08/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599386
Principal investigator 1 ABBVIE INC. $263.25 08/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505051
Principal investigator 1 ABBVIE INC. $29.70 08/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505057
Principal investigator 1 ABBVIE INC. $29.70 08/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202504559
Principal investigator 1 ABBVIE INC. $105.54 08/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202504211
Principal investigator 1 ABBVIE INC. $165.00 08/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503683
Principal investigator 1 ABBVIE INC. $29.70 08/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503685
Principal investigator 1 ABBVIE INC. $74,773.00 08/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502306
Principal investigator 1 ABBVIE INC. $31.05 08/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502456
Principal investigator 1 ABBVIE INC. $8,232.60 08/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202503517
Principal investigator 1 ABBVIE INC. $29.70 08/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501106
Principal investigator 1 ABBVIE INC. $74.25 08/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202501166
Principal investigator 1 ABBVIE INC. $101.25 08/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202501168
Principal investigator 1 ABBVIE INC. $263.25 08/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202501256
Principal investigator 1 ABBVIE INC. $31.05 08/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502158
Principal investigator 1 ABBVIE INC. $31.05 08/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502160
Principal investigator 1 Incyte Corporation $1.06 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599336
Principal investigator 1 Incyte Corporation $54.76 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599344
Principal investigator 1 Incyte Corporation $64.72 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599348
Principal investigator 1 Incyte Corporation $62.27 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599360
Principal investigator 1 Incyte Corporation $45.80 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599364
Principal investigator 1 Incyte Corporation $54.76 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599368
Principal investigator 1 Incyte Corporation $11.45 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599370
Principal investigator 1 Incyte Corporation $5.30 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599374
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599378
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599382
Principal investigator 1 Incyte Corporation $59.13 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599388
Principal investigator 1 Incyte Corporation $4.86 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599395
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599417
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599421
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599423
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599426
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599428
Principal investigator 1 Incyte Corporation $16.44 08/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599430
Principal investigator 1 Incyte Corporation $44.00 08/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599260
Principal investigator 1 Incyte Corporation $2,500.00 07/31/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599661
Principal investigator 1 Incyte Corporation $3,500.00 07/31/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599665
Principal investigator 1 Incyte Corporation $14,000.00 07/31/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599669
Principal investigator 1 ABBVIE INC. $31.05 07/30/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202500436
Principal investigator 1 ABBVIE INC. $101.25 07/30/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202500468
Principal investigator 1 ABBVIE INC. $2,500.00 07/29/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202500290
Principal investigator 1 Incyte Corporation $70.00 07/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599256
Principal investigator 1 Incyte Corporation $100.00 07/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599270
Principal investigator 1 ABBVIE INC. $105.54 07/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202499468
Principal investigator 1 ABBVIE INC. $29.70 07/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202499484
Principal investigator 1 ABBVIE INC. $2,500.00 07/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202499486
Principal investigator 1 ABBVIE INC. $436.80 07/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202499536
Principal investigator 1 Incyte Corporation $2,104.00 07/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599294
Principal investigator 1 Incyte Corporation $1,985.00 07/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599298
Principal investigator 1 Incyte Corporation $1,985.00 07/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599400
Principal investigator 1 ABBVIE INC. $29.70 07/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202498582
Principal investigator 1 ABBVIE INC. $29.70 07/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202498182
Principal investigator 1 ABBVIE INC. $2,500.00 07/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202498300
Principal investigator 1 Incyte Corporation $350.00 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599266
Principal investigator 1 Incyte Corporation $100.00 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599278
Principal investigator 1 Incyte Corporation $70.00 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599281
Principal investigator 1 Incyte Corporation $100.00 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599306
Principal investigator 1 Incyte Corporation $1,783.00 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599310
Principal investigator 1 Incyte Corporation $100.00 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599403
Principal investigator 1 Incyte Corporation $100.00 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599407
Principal investigator 1 Incyte Corporation $100.00 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599411
Principal investigator 1 ABBVIE INC. $2,104.05 07/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497026
Principal investigator 1 ABBVIE INC. $86.60 07/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202497042
Principal investigator 1 ABBVIE INC. $165.00 07/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496954
Principal investigator 1 Incyte Corporation $2,038.00 07/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240599673
Principal investigator 1 ABBVIE INC. $7,895.10 07/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202494787
Principal investigator 1 ABBVIE INC. $30,309.20 07/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496613
Principal investigator 1 ABBVIE INC. $29.70 07/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202493731
Principal investigator 1 Incyte Corporation $49.36 07/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599314
Principal investigator 1 Incyte Corporation $68.70 07/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599328
Principal investigator 1 Incyte Corporation $0.31 07/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599332
Principal investigator 1 Incyte Corporation $22.90 07/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599352
Principal investigator 1 Incyte Corporation $11.45 07/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599356
Principal investigator 1 Incyte Corporation $24.68 07/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599392
Principal investigator 1 Incyte Corporation $16.18 07/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599414
Principal investigator 1 ABBVIE INC. $29.70 06/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202492897
Principal investigator 1 Incyte Corporation $350.00 06/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598806
Principal investigator 1 Incyte Corporation $3,041.00 06/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598898
Principal investigator 1 Incyte Corporation $1,985.00 06/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598902
Principal investigator 1 Incyte Corporation $2,934.00 06/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599172
Principal investigator 1 Incyte Corporation $3,041.00 06/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599184
Principal investigator 1 Incyte Corporation $3,041.00 06/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599189
Principal investigator 1 Incyte Corporation $100.00 06/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598809
Principal investigator 1 Incyte Corporation $350.00 06/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598813
Principal investigator 1 Incyte Corporation $44.00 06/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598916
Principal investigator 1 Incyte Corporation $2,113.00 06/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598925
Principal investigator 1 ABBVIE INC. $1,100.00 06/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202492267
Principal investigator 1 ABBVIE INC. $29.70 06/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202492283
Principal investigator 1 ABBVIE INC. $337.50 06/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202492285
Principal investigator 1 ABBVIE INC. $105.54 06/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202492305
Principal investigator 1 ABBVIE INC. $263.25 06/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202491887
Principal investigator 1 ABBVIE INC. $495.00 06/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202490897
Principal investigator 1 Incyte Corporation $1,783.00 06/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598937
Principal investigator 1 Incyte Corporation $1,500.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598920
Principal investigator 1 Incyte Corporation $70.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598928
Principal investigator 1 Incyte Corporation $8,100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598941
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599103
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599106
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599111
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599116
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599119
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599123
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599126
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599130
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599135
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599141
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599146
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599151
Principal investigator 1 Incyte Corporation $100.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599154
Principal investigator 1 Incyte Corporation $70.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599220
Principal investigator 1 Incyte Corporation $70.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599224
Principal investigator 1 Incyte Corporation $70.00 06/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599228
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 06/04/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283784
Principal investigator 1 Janssen Research & Development, LLC $1,131.00 06/04/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283792
Principal investigator 1 Janssen Research & Development, LLC $750.00 06/04/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283804
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 06/04/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283865
Principal investigator 1 ABBVIE INC. $5,761.35 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202489357
Principal investigator 1 ABBVIE INC. $6,939.31 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489435
Principal investigator 1 ABBVIE INC. $2,116.20 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489437
Principal investigator 1 Incyte Corporation $38.11 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598874
Principal investigator 1 Incyte Corporation $34.35 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599038
Principal investigator 1 Incyte Corporation $3.09 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599046
Principal investigator 1 Incyte Corporation $11.45 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240599059
Principal investigator 1 ABBVIE INC. $92.01 05/30/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202487139
Principal investigator 1 ABBVIE INC. $44.55 05/29/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487047
Principal investigator 1 ABBVIE INC. $29.70 05/29/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487067
Principal investigator 1 ABBVIE INC. $29.70 05/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202486267
Principal investigator 1 ABBVIE INC. $105.54 05/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202485657
Principal investigator 1 Incyte Corporation $250.00 05/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598829
Principal investigator 1 Incyte Corporation $2,934.00 05/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598853
Principal investigator 1 Incyte Corporation $1,985.00 05/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598891
Principal investigator 1 Incyte Corporation $1,985.00 05/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599249
Principal investigator 1 Incyte Corporation $1,972.00 05/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598866
Principal investigator 1 Incyte Corporation $2,613.00 05/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598886
Principal investigator 1 Incyte Corporation $200.00 05/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598817
Principal investigator 1 Incyte Corporation $300.00 05/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598833
Principal investigator 1 Incyte Corporation $5,600.00 05/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598878
Principal investigator 1 Incyte Corporation $4,000.00 05/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598882
Principal investigator 1 Incyte Corporation $44.00 05/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598894
Principal investigator 1 Incyte Corporation $1,500.00 05/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599180
Principal investigator 1 ABBVIE INC. $31.05 05/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202484467
Principal investigator 1 ABBVIE INC. $86.60 05/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202484477
Principal investigator 1 ABBVIE INC. $101.25 05/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202484479
Principal investigator 1 ABBVIE INC. $29.70 05/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202484491
Principal investigator 1 ABBVIE INC. $350.00 05/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202484493
Principal investigator 1 ABBVIE INC. $10,903.65 05/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483741
Principal investigator 1 ABBVIE INC. $101.25 05/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483743
Principal investigator 1 ABBVIE INC. $40,813.08 05/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483965
Principal investigator 1 ABBVIE INC. $18,056.85 05/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202483967
Principal investigator 1 Incyte Corporation $1,783.00 05/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598870
Principal investigator 1 Incyte Corporation $2,517.00 05/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598906
Principal investigator 1 Incyte Corporation $1,985.00 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598909
Principal investigator 1 Incyte Corporation $1,985.00 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598912
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599042
Principal investigator 1 Incyte Corporation $148.85 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599073
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599078
Principal investigator 1 Incyte Corporation $16.18 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599083
Principal investigator 1 Incyte Corporation $8.48 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599089
Principal investigator 1 Incyte Corporation $74.04 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599193
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599197
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599201
Principal investigator 1 ABBVIE INC. $44.55 05/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202480827
Principal investigator 1 ABBVIE INC. $337.50 05/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202480841
Principal investigator 1 ABBVIE INC. $86.60 04/30/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202480543
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 04/30/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283820
Principal investigator 1 Janssen Research & Development, LLC $2,995.00 04/28/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283808
Principal investigator 1 ABBVIE INC. $29.70 04/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202479509
Principal investigator 1 ABBVIE INC. $436.80 04/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202479056
Principal investigator 1 ABBVIE INC. $29.70 04/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202479060
Principal investigator 1 ABBVIE INC. $75.00 04/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202479067
Principal investigator 1 Amgen Inc. $61,394.99 04/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246649191
Principal investigator 1 ABBVIE INC. $350.00 04/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202478623
Principal investigator 1 ABBVIE INC. $86.60 04/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202477415
Principal investigator 1 ABBVIE INC. $44.55 04/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202477487
Principal investigator 1 ABBVIE INC. $105.54 04/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202476937
Principal investigator 1 Incyte Corporation $1,972.00 04/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598836
Principal investigator 1 Incyte Corporation $90.00 04/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598842
Principal investigator 1 ABBVIE INC. $31.05 04/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202475668
Principal investigator 1 ABBVIE INC. $31.05 04/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202475673
Principal investigator 1 ABBVIE INC. $31.05 04/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202475723
Principal investigator 1 ABBVIE INC. $101.25 04/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202475790
Principal investigator 1 ABBVIE INC. $29.70 04/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202475121
Principal investigator 1 ABBVIE INC. $86.60 04/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202474909
Principal investigator 1 Janssen Research & Development, LLC $100.00 04/04/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283836
Principal investigator 1 ABBVIE INC. $44.55 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470337
Principal investigator 1 ABBVIE INC. $3,932.70 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470716
Principal investigator 1 ABBVIE INC. $29.70 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202471095
Principal investigator 1 ABBVIE INC. $29.70 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202471098
Principal investigator 1 ABBVIE INC. $44.55 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202471103
Principal investigator 1 ABBVIE INC. $350.00 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202471265
Principal investigator 1 ABBVIE INC. $35,038.98 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202471671
Principal investigator 1 Incyte Corporation $2,934.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598820
Principal investigator 1 Incyte Corporation $1,985.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598825
Principal investigator 1 Incyte Corporation $1,985.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598845
Principal investigator 1 Incyte Corporation $550.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598850
Principal investigator 1 Incyte Corporation $350.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598858
Principal investigator 1 Incyte Corporation $4,000.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598862
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598933
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598945
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598949
Principal investigator 1 Incyte Corporation $5.30 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598955
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598959
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598962
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598966
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598971
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598974
Principal investigator 1 Incyte Corporation $127.20 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598978
Principal investigator 1 Incyte Corporation $42.40 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598981
Principal investigator 1 Incyte Corporation $53.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598984
Principal investigator 1 Incyte Corporation $15.90 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598988
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598992
Principal investigator 1 Incyte Corporation $10.60 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598996
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599000
Principal investigator 1 Incyte Corporation $37.10 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599005
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599010
Principal investigator 1 Incyte Corporation $58.30 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599014
Principal investigator 1 Incyte Corporation $21.87 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599017
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599021
Principal investigator 1 Incyte Corporation $18.54 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599026
Principal investigator 1 Incyte Corporation $0.93 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599029
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599034
Principal investigator 1 Incyte Corporation $34.35 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599051
Principal investigator 1 Incyte Corporation $249.08 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599055
Principal investigator 1 Incyte Corporation $59.13 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599063
Principal investigator 1 Incyte Corporation $118.26 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599066
Principal investigator 1 Incyte Corporation $24.30 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599070
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599086
Principal investigator 1 Incyte Corporation $79.50 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599092
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599095
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599099
Principal investigator 1 Incyte Corporation $124.54 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599158
Principal investigator 1 Incyte Corporation $132.50 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599162
Principal investigator 1 Incyte Corporation $48.54 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599168
Principal investigator 1 Incyte Corporation $44.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599175
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599205
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599209
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599212
Principal investigator 1 Incyte Corporation $1,985.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599217
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599232
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599238
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599241
Principal investigator 1 Incyte Corporation $4,000.00 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599245
Principal investigator 1 Incyte Corporation $58.30 04/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240599253
Principal investigator 1 ABBVIE INC. $86.60 03/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202466799
Principal investigator 1 ABBVIE INC. $350.00 03/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202464321
Principal investigator 1 ABBVIE INC. $75.00 03/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202464325
Principal investigator 1 ABBVIE INC. $86.60 03/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202463967
Principal investigator 1 ABBVIE INC. $86.60 03/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202463970
Principal investigator 1 ABBVIE INC. $350.00 03/13/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202463218
Principal investigator 1 ABBVIE INC. $86.60 03/13/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202463291
Principal investigator 1 ABBVIE INC. $44.55 03/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462693
Principal investigator 1 ABBVIE INC. $75.00 03/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462697
Principal investigator 1 ABBVIE INC. $29.70 03/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462730
Principal investigator 1 Incyte Corporation $2,004.00 03/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598600
Principal investigator 1 ABBVIE INC. $29.70 03/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462332
Principal investigator 1 ABBVIE INC. $29.70 03/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462344
Principal investigator 1 ABBVIE INC. $350.00 03/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462357
Principal investigator 1 ABBVIE INC. $29.70 03/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462364
Principal investigator 1 ABBVIE INC. $44.55 03/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462369
Principal investigator 1 ABBVIE INC. $460.65 03/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462538
Principal investigator 1 ABBVIE INC. $9,718.35 03/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202460508
Principal investigator 1 ABBVIE INC. $1,920.45 03/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202461815
Principal investigator 1 ABBVIE INC. $350.00 03/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202457512
Principal investigator 1 ABBVIE INC. $750.00 03/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202457515
Principal investigator 1 ABBVIE INC. $263.25 03/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202455827
Principal investigator 1 Incyte Corporation $1,985.00 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598617
Principal investigator 1 Incyte Corporation $2,342.00 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598642
Principal investigator 1 Incyte Corporation $1,985.00 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598667
Principal investigator 1 Incyte Corporation $59.13 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598681
Principal investigator 1 Incyte Corporation $4.24 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598685
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598690
Principal investigator 1 Incyte Corporation $54.76 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598697
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598707
Principal investigator 1 Incyte Corporation $45.80 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598735
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598768
Principal investigator 1 Incyte Corporation $2,738.00 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598772
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598788
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598791
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598794
Principal investigator 1 ABBVIE INC. $11,078.11 02/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202454660
Principal investigator 1 Janssen Research & Development, LLC $2,995.00 02/27/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283845
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 02/27/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283857
Principal investigator 1 ABBVIE INC. $750.00 02/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202453669
Principal investigator 1 Incyte Corporation $1,128.00 02/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598608
Principal investigator 1 Incyte Corporation $2,004.00 02/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598729
Principal investigator 1 ABBVIE INC. $750.00 02/13/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202451504
Principal investigator 1 ABBVIE INC. $101.25 02/13/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202451528
Principal investigator 1 Incyte Corporation $90.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598533
Principal investigator 1 Incyte Corporation $100.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598542
Principal investigator 1 Incyte Corporation $100.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598546
Principal investigator 1 Incyte Corporation $100.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598550
Principal investigator 1 Incyte Corporation $100.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598554
Principal investigator 1 Incyte Corporation $4,000.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598613
Principal investigator 1 Incyte Corporation $44.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598625
Principal investigator 1 Incyte Corporation $44.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598630
Principal investigator 1 Incyte Corporation $70.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598634
Principal investigator 1 Incyte Corporation $70.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598638
Principal investigator 1 ABBVIE INC. $263.25 02/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202449506
Principal investigator 1 ABBVIE INC. $13,471.50 02/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202449587
Principal investigator 1 ABBVIE INC. $9,172.20 02/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202449592
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598646
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598655
Principal investigator 1 Incyte Corporation $4.25 02/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598670
Principal investigator 1 Incyte Corporation $52.48 02/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598678
Principal investigator 1 ABBVIE INC. $29.70 02/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202443851
Principal investigator 1 Amgen Inc. $1,850.00 01/30/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) No dispute reported 06/30/2026 1246649199
Principal investigator 1 Janssen Research & Development, LLC $750.00 01/29/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283779
Principal investigator 1 ABBVIE INC. $165.22 01/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202441683
Principal investigator 1 Amgen Inc. $30,636.71 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246649195
Principal investigator 1 Incyte Corporation $2,934.00 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598567
Principal investigator 1 Incyte Corporation $1,985.00 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598579
Principal investigator 1 Incyte Corporation $1,985.00 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598582
Principal investigator 1 Incyte Corporation $2,111.00 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598586
Principal investigator 1 Incyte Corporation $2,111.00 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598588
Principal investigator 1 Incyte Corporation $2,934.00 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598604
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 01/27/2025 Non-covered Recipient Entity
Tx Derm Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175283813
Principal investigator 1 Incyte Corporation $1,972.00 01/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598621
Principal investigator 1 ABBVIE INC. $31.05 01/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202440594
Principal investigator 1 ABBVIE INC. $31.05 01/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202440601
Principal investigator 1 Incyte Corporation $1,878.00 01/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598476
Principal investigator 1 Incyte Corporation $1,920.00 01/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598484
Principal investigator 1 ABBVIE INC. $132.30 01/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202439519
Principal investigator 1 ABBVIE INC. $750.00 01/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202439536
Principal investigator 1 ABBVIE INC. $31.05 01/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202439540
Principal investigator 1 Incyte Corporation $1,985.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598480
Principal investigator 1 Incyte Corporation $2,111.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598488
Principal investigator 1 Incyte Corporation $1,985.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598492
Principal investigator 1 Incyte Corporation $350.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598500
Principal investigator 1 Incyte Corporation $70.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598515
Principal investigator 1 Incyte Corporation $70.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598518
Principal investigator 1 Incyte Corporation $154.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598521
Principal investigator 1 Incyte Corporation $154.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598525
Principal investigator 1 Incyte Corporation $154.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598528
Principal investigator 1 Incyte Corporation $750.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598702
Principal investigator 1 Incyte Corporation $2,934.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598739
Principal investigator 1 Incyte Corporation $100.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598743
Principal investigator 1 Incyte Corporation $100.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598746
Principal investigator 1 Incyte Corporation $100.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598750
Principal investigator 1 Incyte Corporation $100.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598755
Principal investigator 1 Incyte Corporation $100.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598758
Principal investigator 1 Incyte Corporation $100.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598762
Principal investigator 1 Incyte Corporation $100.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598765
Principal investigator 1 Incyte Corporation $2,111.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598797
Principal investigator 1 Incyte Corporation $70.00 01/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598802
Principal investigator 1 ABBVIE INC. $350.00 01/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202438519
Principal investigator 1 ABBVIE INC. $29.70 01/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202438523
Principal investigator 1 ABBVIE INC. $350.00 01/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202438527
Principal investigator 1 ABBVIE INC. $150.00 01/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202437763
Principal investigator 1 ABBVIE INC. $29.70 01/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202437780
Principal investigator 1 ABBVIE INC. $29.70 01/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202437785
Principal investigator 1 ABBVIE INC. $44.55 01/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202437788
Principal investigator 1 ABBVIE INC. $29.70 01/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202437805
Principal investigator 1 Incyte Corporation $44.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598495
Principal investigator 1 Incyte Corporation $350.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598504
Principal investigator 1 Incyte Corporation $4,000.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598508
Principal investigator 1 Incyte Corporation $350.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598539
Principal investigator 1 Incyte Corporation $100.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598558
Principal investigator 1 Incyte Corporation $50.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598562
Principal investigator 1 Incyte Corporation $90.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598570
Principal investigator 1 Incyte Corporation $90.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598575
Principal investigator 1 Incyte Corporation $350.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598592
Principal investigator 1 Incyte Corporation $650.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598596
Principal investigator 1 Incyte Corporation $92.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598659
Principal investigator 1 Incyte Corporation $750.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598693
Principal investigator 1 Incyte Corporation $500.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598726
Principal investigator 1 Incyte Corporation $300.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598731
Principal investigator 1 Incyte Corporation $750.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598776
Principal investigator 1 Incyte Corporation $750.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598780
Principal investigator 1 Incyte Corporation $278.00 01/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240598785
Principal investigator 1 ABBVIE INC. $44.55 01/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202437054
Principal investigator 1 ABBVIE INC. $263.25 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202435841
Principal investigator 1 ABBVIE INC. $337.50 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202435911
Principal investigator 1 ABBVIE INC. $29.70 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202435955
Principal investigator 1 ABBVIE INC. $337.50 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202435981
Principal investigator 1 Incyte Corporation $9.54 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598650
Principal investigator 1 Incyte Corporation $124.54 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598663
Principal investigator 1 Incyte Corporation $19.57 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598673
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598710
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598714
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598718
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY RESEARCH CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240598721